ATE431149T1 - Analoge der barbitursäure als therapeutische wirkstoffe - Google Patents

Analoge der barbitursäure als therapeutische wirkstoffe

Info

Publication number
ATE431149T1
ATE431149T1 AT01934202T AT01934202T ATE431149T1 AT E431149 T1 ATE431149 T1 AT E431149T1 AT 01934202 T AT01934202 T AT 01934202T AT 01934202 T AT01934202 T AT 01934202T AT E431149 T1 ATE431149 T1 AT E431149T1
Authority
AT
Austria
Prior art keywords
barbituric acid
analogue
active ingredients
therapeutic active
inhibit
Prior art date
Application number
AT01934202T
Other languages
English (en)
Inventor
Belin Jackie Y De
Maria-Rosario Romero-Martin
Paul Finn
Lee Sayers
Norman Law
David Billington
Stephen Ryley
Shoumo Bhattacharya
Original Assignee
Novuspharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novuspharma Spa filed Critical Novuspharma Spa
Application granted granted Critical
Publication of ATE431149T1 publication Critical patent/ATE431149T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01934202T 2000-06-05 2001-06-05 Analoge der barbitursäure als therapeutische wirkstoffe ATE431149T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013655.6A GB0013655D0 (en) 2000-06-05 2000-06-05 Therapeutic compounds
PCT/GB2001/002468 WO2001093841A2 (en) 2000-06-05 2001-06-05 Barbituric acid analogs as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE431149T1 true ATE431149T1 (de) 2009-05-15

Family

ID=9893008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01934202T ATE431149T1 (de) 2000-06-05 2001-06-05 Analoge der barbitursäure als therapeutische wirkstoffe

Country Status (14)

Country Link
US (2) US20030229108A1 (de)
EP (1) EP1305026B1 (de)
JP (1) JP2003535123A (de)
CN (1) CN1433312A (de)
AT (1) ATE431149T1 (de)
AU (1) AU2001260504A1 (de)
BR (1) BR0111438A (de)
CA (1) CA2410311C (de)
DE (1) DE60138709D1 (de)
GB (1) GB0013655D0 (de)
IL (1) IL153014A0 (de)
NZ (1) NZ522779A (de)
WO (1) WO2001093841A2 (de)
ZA (1) ZA200209439B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2384428A (en) * 2002-01-29 2003-07-30 Thromb X Nv Inhibitors of HIF
US7288546B1 (en) * 2003-02-20 2007-10-30 University Of Central Florida Method and compound for inhibition of cell death
WO2003074497A1 (en) * 2002-03-01 2003-09-12 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
GB2386892A (en) * 2002-03-28 2003-10-01 Pantherix Ltd Carboxy containing (phenyl-/heterocyclyl-)methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
ES2527068T3 (es) 2002-10-23 2015-01-19 University Of Utah Research Foundation Análisis de fusión de amplicones con colorantes de saturación
ATE458485T1 (de) 2003-07-11 2010-03-15 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
US9657347B2 (en) 2004-04-20 2017-05-23 University of Utah Research Foundation and BioFire Defense, LLC Nucleic acid melting analysis with saturation dyes
AU2005306325A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
US8309523B2 (en) * 2007-11-21 2012-11-13 Vib Vzw Inhibitors of MALT1 proteolytic activity and uses thereof
KR100965726B1 (ko) * 2007-11-23 2010-06-24 재단법인서울대학교산학협력재단 피리미딘-2,4,6-트라이온 유도체를 함유하는 Ｈｓｐ９０억제제 및 이를 이용한 항암제
EP2271341B1 (de) * 2008-05-08 2016-08-17 Nova Southeastern University Spezifische inhibitoren für vaskuläre endothel-wachstumsfaktor-rezeptoren
WO2010018458A2 (en) * 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
US8304421B2 (en) * 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
WO2012065139A2 (en) * 2010-11-11 2012-05-18 Board Of Regents, The University Of Texas System Entpd5 inhibitors
WO2013024447A1 (en) 2011-08-18 2013-02-21 Nuhope, Llc Compounds for use in cancer therapy
GEP201706656B (en) 2011-11-11 2017-04-25 Pfizer 2-thiopyrimidinones
WO2014047232A2 (en) * 2012-09-21 2014-03-27 Cornell University C-rel inhibitors and uses thereof
EP2938342A4 (de) 2012-12-28 2016-06-15 Univ Arkansas Indolverbindungen zur verwendung bei der behandlung von entzündungen und krebs
SG11201508054UA (en) 2013-04-19 2015-11-27 Univ Arkansas Combretastatin analogs
US20160075689A1 (en) * 2013-04-23 2016-03-17 The Board Of Trustees Of The University Of Arkansas Polymerase, endonuclease, and helicase inhibitors and methods of using thereof
PT3049085T (pt) 2013-09-26 2021-10-01 Beth Israel Deaconess Medical Ct Inc Inibidores de sgk1 no tratamento da síndrome do qt longo
US9145374B2 (en) * 2013-11-20 2015-09-29 National Tsing Hua University Shikimate pathway inhibitors and the use thereof
US20170128449A1 (en) * 2014-03-27 2017-05-11 Kyoto University Medicinal composition inhibiting neovascularization proliferation factor
AU2015240880A1 (en) 2014-03-31 2016-09-15 Bioventures, Llc Disubstituted triazole analogs
WO2015195951A1 (en) * 2014-06-18 2015-12-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Combination therapy to enhance the anticancer efficacy of platinum drugs
SG11201705952SA (en) * 2015-02-04 2017-09-28 Beyondbio Inc Heterocyclic compound and pharmaceutical composition comprising same
MA42035A (fr) 2015-05-05 2018-03-14 Pfizer 2-thiopyrimidinones
US12552763B2 (en) 2017-02-02 2026-02-17 Bioventures, Llc Methods of protecting against neurodegeneration
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
EP3947351B1 (de) * 2019-03-29 2026-03-11 Board of Regents, The University of Texas System Kleinmolekulare parg-inhibitoren und verfahren zu deren verwendung
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331687A (en) * 1962-09-24 1967-07-18 Render Belipa G M B H Fa Electrophotographic material
DE2042663A1 (de) * 1970-08-28 1972-03-02 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches Trockenkopierverfahren
PL77134B1 (de) * 1971-12-29 1975-02-28
US3819595A (en) * 1972-09-05 1974-06-25 Dow Chemical Co Nucleation of normally crystalline vinylidene chloride polymers
SU1129202A1 (ru) * 1981-09-08 1984-12-15 Предприятие П/Я Г-4740 Способ получени 2-арилиденкарбонильных соединений
JPS6229570A (ja) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
JPH0196628A (ja) * 1987-10-08 1989-04-14 Idemitsu Kosan Co Ltd 有機非線型光学材料
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
JPH1048824A (ja) * 1996-07-31 1998-02-20 Toyobo Co Ltd 光重合性組成物、それを用いた感光性原版およびその露光方法
US6440985B1 (en) * 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
EP1198255B1 (de) * 1999-06-04 2008-01-16 Dana-Farber Cancer Institute, Inc. Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren

Also Published As

Publication number Publication date
JP2003535123A (ja) 2003-11-25
EP1305026A2 (de) 2003-05-02
GB0013655D0 (en) 2000-07-26
US20080113993A1 (en) 2008-05-15
CA2410311C (en) 2009-12-29
ZA200209439B (en) 2003-11-20
WO2001093841A3 (en) 2002-06-06
CA2410311A1 (en) 2001-12-13
US20030229108A1 (en) 2003-12-11
WO2001093841A2 (en) 2001-12-13
BR0111438A (pt) 2003-06-17
DE60138709D1 (de) 2009-06-25
AU2001260504A1 (en) 2001-12-17
IL153014A0 (en) 2003-06-24
CN1433312A (zh) 2003-07-30
NZ522779A (en) 2004-08-27
EP1305026B1 (de) 2009-05-13

Similar Documents

Publication Publication Date Title
DE60138709D1 (de) Analoge der barbitursäure als therapeutische wirkstoffe
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
SE0001899D0 (sv) New compounds
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
ES2195344T3 (es) Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
PT994710E (pt) Composicoes farmaceuticas administraveis por via oral incluindo uma benzidrilpiperazina e uma ciclodextrina
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
SE0100569D0 (sv) New compounds
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
BG106155A (en) Novel derivatives and analogues of galanthamin
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
ATE253359T1 (de) Antithrombotische mittel
ATE371737T1 (de) Proteaseresistente flint-analoge
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
ATE286395T1 (de) Antithrombotische mittel
DK0853476T3 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse
IT1302289B1 (it) Composizioni farmaceutiche ad attivita' antineoplastica
ATE335491T1 (de) Arzneimittel gegen glomerulosclerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties